U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
  FAQs Site Map About MedelinePlus Contact Us
español
Reuters Health Information Logo

Topiramate safely prevents migraine in adolescents

Printer-friendly version E-mail this page to a friend

Reuters Health

Friday, March 13, 2009

NEW YORK (Reuters Health) - Topiramate is safe and effective in preventing migraine in 12- to 17-year-old patients, according to a report in the journal Pediatrics.

While topiramate is FDA-approved for migraine prophylaxis in adults, the authors explain, there are no approved drugs for migraine prophylaxis in pediatric patients.

Dr. Donald Lewis from Eastern Virginia Medical School, Norfolk, and colleagues evaluated the efficacy and safety of topiramate (50 milligrams/day and 100 milligrams/day) as migraine prophylaxis in 106 patients 12 to 17 years of age.

The higher dose of topiramate significantly reduced the monthly migraine attack rate from an average mean of 4.3 to 1.3 attacks, the authors report, whereas the lower dose did not differ from placebo (attacks reduced from an average of 4.1 to 2.3 in both groups).

In the last 4 weeks of the double-blind phase of the study, more than half the subjects in the 100 milligrams/day topiramate group remained migraine free.

The responder rate was 83 percent for the 100 milligrams/day topiramate group, the researchers note, but only 46 percent for the 50 milligrams/day topiramate group and 45 percent for the placebo group.

Nearly three quarters of the patients in both topiramate groups experienced adverse events, compared with less than half of the patients in the placebo group, with the topiramate groups experiencing more upper respiratory tract infection, paresthesia, and dizziness.

"Safety analyses revealed no unexpected findings," the investigators conclude. "The results of this trial demonstrated that 100 milligrams/day topiramate showed efficacy in the prevention of migraine in pediatric subjects."

SOURCE: Pediatrics, March 2009.


Reuters Health

© 2009 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies. For additional information on other Reuters media services please visit http://about.reuters.com/media/.

Related News:
More News on this Date

Related MedlinePlus Pages: